SFXN1 and myeloid sarcoma: More specifically, immunohistochemical analysis of MS plaques of patients with progressive MS revealed the presence of several complement proteins (C3, fB, C1q), activation products (C3b, iC3b, C4d, TCC) as well as regulators (fH, C1 inhibitor, clusterin) (13).